Cardiol Therapeutics, Inc. (CRDL.CA) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a clinical-stage Canadian biopharmaceutical company founded in 2017 and headquartered in Oakville, Ontario. The company went public in January 2019 and focuses on developing innovative therapies to treat cardiovascular diseases through anti-fibrotic and anti-inflammatory approaches. As a clinical-stage company, Cardiol has no commercial products yet and is currently conducting Phase II/III trials for its lead drug candidate, CardiolRx, targeting heart-related conditions including COVID-19 cardiovascular complications and acute myocarditis.

Ask drillr about Cardiol Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−36.67M

Op. CF (TTM)

−24.07M

Latest newsMore news →

Cardiol Therapeutics announced the exercise of warrants for over USD 7 million in proceeds, strengthening its balance sheet ahead of Phase III MAVERIC trial data in recurrent pericarditis.4d ago

Cardiol Therapeutics filed a preliminary short form base shelf prospectus for up to US$150 million with Canadian securities regulators and a corresponding Form F-10 registration statement with the US SEC.10d ago

Latest newsMore news →

Cardiol Therapeutics announced the exercise of warrants for over USD 7 million in proceeds, strengthening its balance sheet ahead of Phase III MAVERIC trial data in recurrent pericarditis.4d ago Cardiol Therapeutics filed a preliminary short form base shelf prospectus for up to US$150 million with Canadian securities regulators and a corresponding Form F-10 registration statement with the US SEC.10d ago